Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Base Pair Biotechnologies
AddedFeb 16, 2024
UpdatedJun 18, 2026
Base Pair Biotechnologies

Base Pair Biotechnologies

Base Pair Biotechnologies: Rapid, high-quality RNA/DNA-based aptamer ligand discovery.

HQ
Pearland, TX, US
Founded
2011
Overview
Compare
Fundraising
Employees
Website

Base Pair Biotechnologies, founded with a mission to revolutionize ligand discovery, focuses on providing rapid, high-quality RNA- and DNA-based aptamer discovery services. The company's core offerings include custom aptamer discovery and development, bioinformatics for aptamer selection, affinity determination, and assay development services. Their market focus spans biotechnology, pharmaceuticals, and diagnostics, leveraging aptamers' advantages over traditional antibodies for various applications.

Notable affiliated individuals and investors include experts in biotechnology and life sciences, though specific names are not disclosed. Key achievements include the development of proprietary tools like AptaTracker™ for enhanced aptamer selection and maturation processes. Base Pair Biotechnologies has significantly impacted the field by accelerating the discovery of high-affinity ligands, facilitating advancements in diagnostics and therapeutic development.

Base Pair Biotechnologies - Quick Facts

When was Base Pair Biotechnologies founded?

Base Pair Biotechnologies was founded in 2011.

Where is Base Pair Biotechnologies' headquarters located?

Base Pair Biotechnologies' headquarters is located in Pearland, TX, US.

How much has Base Pair Biotechnologies raised to-date?

As of Sep 27, 2023, Base Pair Biotechnologies has raised a total of $3.2M (USD).

How many employees does Base Pair Biotechnologies have?

Base Pair Biotechnologies has 8 employees as of Feb 5, 2024.

Base Pair Biotechnologies - Classification

Industry
  • Professional Service Companies
Technology
  • Bioinformatics
Geographic Exposure
  • Global
Customer
  • Enterprise
Main Product
  • Aptamer Discovery
Tags
  • API
  • Biotech
  • Consulting
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
ISIC
  • 7210Research and experimental development on natural sciences and engineering
Show 11 more industry codes
NAICS
  • 513200Software Publishers
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 513000Publishing Industries
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8731Commercial Physical and Biological Research